Path: treatments/sting-inhibitor-therapy
STING (Stimulator of Interferon Genes) inhibitor therapy represents an emerging immunomodulatory strategy targeting the cGAS-STING pathway, a key driver of chronic neuroinflammation in neurodegenerative diseases. By blocking type I interferon responses downstream of cGAS activation, STING inhibitors offer a novel approach to mitigating microglial activation and neuroinflammation in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
The cGAS-STING pathway serves as a major cytosolic DNA sensing mechanism:
STING inhibitors block this pathway at the STING level:
By preventing STING activation, these inhibitors reduce:
Multiple studies demonstrate STING inhibition benefits in AD models[8][9]:
STING pathway involvement in PD is supported by preclinical data[10][11]:
Emerging evidence links cGAS-STING to ALS pathophysiology[12][13]:
| Compound | Developer | Phase | Indication | Status |
|---|---|---|---|---|
| H-151 | Novartis | Phase 1 | Healthy volunteers | Completed |
| AST-008 | AiCuris | Phase 1 | Solid tumors | Completed |
| GS-5745 | Gilead | Phase 1/2 | Solid tumors | Active |
| BMS-986302 | BMS | Phase 1 | Autoimmune | Recruiting |
No STING inhibitors are yet in clinical trials for neurodegenerative diseases. However, the strong preclinical data supports potential trials for:
STING inhibitors have demonstrated acceptable safety in oncology trials[14][15]:
STING inhibitors may synergize with other approaches:
STING inhibitor therapy represents a promising immunomodulatory strategy targeting the cGAS-STING pathway, a central driver of chronic neuroinflammation in Alzheimer's disease, Parkinson's disease, and ALS. Strong preclinical evidence demonstrates reduction in neuroinflammation and neuronal protection, supporting clinical development for neurodegenerative indications. Key challenges include optimizing brain penetration and identifying patient populations most likely to benefit.
Sun et al. cGAS is an cytosolic DNA sensor (2013). 2013. ↩︎
Wu et al. STING undergoes conformational changes upon cGAMP binding (2013). 2013. ↩︎
Mathurin et al. Type I interferon in neurodegenerative diseases (2020). 2020. ↩︎
Haag et al. STING inhibitor H-151 blocks pathogenic STING activation (2018). 2018. ↩︎
Bang et al. Covalent STING inhibitors block pathological activation (2019). 2019. ↩︎
Merrick et al. AST-008: oral STING agonist/antagonist (2020). 2020. ↩︎
Xie et al. cGAS-STING activation in Alzheimer's disease models (2020). 2020. ↩︎
Chen et al. STING inhibition improves cognition in AD mice (2021). 2021. ↩︎
Sliter et al. STING mediates α-synuclein-induced neurodegeneration (2018). 2018. ↩︎
Zhao et al. The DJ1-Nrf2-STING axis mediates the neuroprotective effects of Withaferin A in Parkinson's disease (2021). 2021. ↩︎
Yu et al. cGAS-STING activation in ALS (2020). 2020. ↩︎
Komarova et al. STING inhibitors in ALS models (2022). 2022. ↩︎